|Bid||1.4500 x 2200|
|Ask||1.4600 x 1800|
|Day's Range||1.4200 - 1.5700|
|52 Week Range||1.4200 - 12.0000|
|Beta (5Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
Forget undervalued stocks, play these top-ranked stocks with rising P/E.